Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Citius Oncology, Inc.NASDAQ: CTOR
Gross Profit · Q2 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q2 FY2026 gross profit was $1.34M, compared with $0 a year earlier. Trailing-twelve-month gross profit was $4.49M.
Context
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near $1.34M or moves back toward the trailing-twelve-month quarterly average of $1.12M.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Gross Profit vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 gross profit of $4.49M is the 5th highest of the 10 companies compared; the peer median is $0.
- Gross profit amounts to 80.1% of revenue for CTOR, versus a peer median of 52.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.77M | +162.7% | +7.1% | 100.0% | |
| LTM Mar 2026 | $54.45M | +23.4% | +31.9% | 50.9% | |
| LTM Mar 2026 | $26.15M | -3.4% | +10.8% | 45.3% | |
| LTM Mar 2026 | $18.61M | -49.0% | -18.0% | 55.0% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $4.49M | — | — | 80.1% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | -$6K | +86.0% | — | — | |
| LTM Mar 2026 | -$28K | +98.4% | — | — | |
| LTM Mar 2026 | -$240K | +97.6% | — | 20.9% | |
| LTM Mar 2026 | -$26.26M | +63.7% | — | 415.8% | |
| Peer median (excluding CTOR) | $0 | +74.9% | +8.9% | 52.9% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.